duloxetine + placebo

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Anxiety

Conditions

Anxiety

Trial Timeline

Aug 1, 2004 → Jun 1, 2005

NCT ID

NCT00475969

About duloxetine + placebo

duloxetine + placebo is a phase 3 stage product being developed by Eli Lilly for Anxiety. The current trial status is completed. This product is registered under clinical trial identifier NCT00475969. Target conditions include Anxiety.

What happened to similar drugs?

19 of 20 similar drugs in Anxiety were approved

Approved (19) Terminated (2) Active (1)

✅Duloxetine + PlaceboEli LillyApproved

✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved

✅Cariprazine + PlaceboAbbVieApproved

✅EscitalopramAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅Quetiapine extended release tablet + PlaceboAstraZenecaApproved

✅QuetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01931475	Phase 3	Completed	Sep 1, 2013	Jun 1, 2015	Osteoarthritis
NCT01451606	Approved	Terminated	Jul 11, 2011	Nov 4, 2015	Pelvis Pain Chronic
NCT01226511	Phase 3	Completed	Jun 1, 2011	Jun 1, 2013	Anxiety Neuroses
NCT01179672	Phase 3	Completed	Apr 1, 2011	Aug 1, 2013	Diabetic Neuropathy, Painful
NCT01237587	Phase 3	Completed	Mar 1, 2011	Nov 28, 2017	Fibromyalgia
NCT01118780	Approved	Completed	Oct 1, 2010	Jul 1, 2012	Generalized Anxiety Disorder
NCT01070329	Approved	Completed	Mar 1, 2010	Mar 1, 2011	Major Depressive Disorder
NCT01000805	Approved	Completed	Nov 1, 2009	Oct 1, 2010	Major Depressive Disorder
NCT01018680	Phase 3	Completed	Nov 1, 2009	Apr 1, 2011	Osteoarthritis Knee Pain
NCT00965081	Approved	Completed	Sep 1, 2009	Nov 1, 2010	Fibromyalgia, Primary
NCT00803361	Phase 3	Completed	Dec 1, 2008	Jan 1, 2010	Generalized Anxiety Disorder
NCT00767806	Phase 3	Completed	Sep 1, 2008	Jul 1, 2009	Chronic Low Back Pain
NCT00433290	Phase 3	Completed	Feb 1, 2007	May 1, 2008	Osteoarthritis Knee Pain
NCT00424593	Phase 3	Completed	Jan 1, 2007	Oct 1, 2008	Back Pain Without Radiation
NCT00457730	Phase 2/3	Completed	Jan 1, 2007	Aug 1, 2012	Multiple Sclerosis
NCT00408876	Phase 3	Completed	Dec 1, 2006	Nov 1, 2007	Back Pain Without Radiation
NCT00408421	Phase 3	Completed	Nov 1, 2006	Oct 1, 2007	Osteoarthritis Knee Pain
NCT00607789	Approved	Completed	Oct 1, 2006	Oct 1, 2009	Binge Eating
NCT00375973	Phase 2/3	Completed	Sep 1, 2006	Mar 1, 2014	Fatigue Syndrome, Chronic
NCT00233025	Phase 3	Completed	Sep 1, 2005	Jun 1, 2007	Fibromyalgia

Competing Products

20 competing products in Anxiety

See all competitors

Product	Company	Stage	Hype Score
Duloxetine + venlafaxine + placebo	Eli Lilly	Phase 3	40
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Duloxetine + Placebo	Eli Lilly	Phase 3	40
duloxetine hydrochloride + placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
Duloxetine Hydrochloride + placebo	Eli Lilly	Phase 3	40
Duloxetine + venlafaxine + placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Phase 3	40
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	43
risperidone oral tablets	Johnson & Johnson	Phase 3	40
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	27
ABBV-932 + Placebo	AbbVie	Phase 1	29
Cariprazine + Placebo	AbbVie	Approved	43
Escitalopram	AbbVie	Approved	43
Quetiapine	AstraZeneca	Approved	43
Quetiapine extended release tablet + Placebo	AstraZeneca	Approved	43
AZD7325 + Radioligand (11C) flumazenil	AstraZeneca	Phase 1	29
AZD7325 + AZD7325 + AZD7325 + Placebo	AstraZeneca	Phase 2	35